

Not for a UK or US audience

Satellite Symposium Sponsored by Novartis  
21<sup>st</sup> Annual ENETS Conference 2024

## Connecting the dots: Charting the course in GEP-NET treatment

Thursday, 14 March 2024

12:30–14:00 CET

Hall F, Austria Center Vienna  
Vienna, Austria

### Our faculty



**Christos Toumpanakis**  
(Chair)

Royal Free Hospital, London,  
United Kingdom



**Simron Singh**

University of Toronto &  
Sunnybrook Health Sciences Centre  
& Institute for Clinical Evaluative  
Sciences, Toronto, Canada



**Niklaus Schaefer**

University of Lausanne &  
Lausanne University Hospital,  
Lausanne, Switzerland

This symposium is organized and fully funded by Novartis. This scientific program and/or material was developed for use outside of the US and UK, intended for non-US and non-UK HCPs licensed to prescribe medicine, and is to be used in accordance with local laws and regulations. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the Summary of Product Characteristics (SmPC) or product information approved in your local country. This scientific information may include data/information on investigational uses of compounds/drugs that have not been approved by regulatory authorities.

Not for a UK or US audience

Satellite Symposium Sponsored by Novartis  
21<sup>st</sup> Annual ENETS Conference 2024

# Connecting the dots: Charting the course in GEP-NET treatment

## Welcome

Join our expert faculty to review the **unmet needs, current treatment landscape, and latest data** for metastatic grade 2 and grade 3 GEP-NETs. We will also explore the **best approach to treatment selection** in this setting considering the multiple prognostic and predictive factors for RLT outcomes and discuss the **importance of multi-disciplinary collaboration** in the management of patients with NETs.

## Agenda

- **Welcome and introduction**  
Christos Toumpanakis
- **Current treatment landscape, unmet needs, and emerging clinical data in metastatic grade 2 and grade 3 GEP-NETs**  
Simron Singh
- **Investigational therapies in GEP-NETs**  
Christos Toumpanakis
- **Helping to improve patient selection by deciphering prognostic/predictive factors for RLT**  
Niklaus Schaefer
- **Panel discussion**  
All
- **Audience Q&A**  
All

This symposium is organized and fully funded by Novartis. This scientific program and/or material was developed for use outside of the US and UK, intended for non-US and non-UK HCPs licensed to prescribe medicine, and is to be used in accordance with local laws and regulations. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the Summary of Product Characteristics (SmPC) or product information approved in your local country. This scientific information may include data/information on investigational uses of compounds/drugs that have not been approved by regulatory authorities.